Tucatinib Combinations in HER2+  Breast Cancer: HER2CLIMB-02 and HER2CLIMB-05

Clinical Brief: Novel Clinical Trial Data in HER2-Positive (HER2+) Metastatic Breast Cancer

Key Themes:

• HER2CLIMB-02 Results: Addition of tucatinib to T-DM1 showed modest progression-free survival (PFS) improvement (9.5 vs 7.4 months) without overall survival benefit
• Subgroup Benefit: More pronounced benefit observed in patients with brain metastases (PFS, 7.8 vs 5.7 months)
• HER2CLIMB-05 Trial: Investigating tucatinib added to maintenance trastuzumab/pertuzumab following first-line THP

Key Points for Physicians:

• HER2CLIMB-02 results support the concept of dual HER2-directed therapy but may not substantially change practice
• The more notable benefit in patients with brain metastases reinforces tucatinib’s value in this population
• HER2CLIMB-05 data may provide insight into whether earlier tucatinib exposure could prevent development of brain metastases

Notable Insights:

• Not all positive trial results immediately change clinical practice, particularly when the benefit is modest
• The field is moving toward bringing effective agents into earlier lines of therapy
• The potential to prevent brain metastases through earlier use of agents with central nervous system (CNS) activity represents an important research direction

Clinical Significance:

Although HER2CLIMB-02 data showed modest benefit overall, the study results reinforce tucatinib’s value in patients with brain metastases and highlight the ongoing evolution of treatment sequencing in HER2+ metastatic breast cancer, with increasing interest in preventive strategies for CNS disease.